Established in 1986, Hadasit is the Technology Transfer Company of Hadassah Medical Organization (Hadassah) in Jerusalem, Israel.
Our Mission - IP Commercialization
Hadasit’s mission is to promote and commercialize the vast intellectual property and R&D capabilities generated at Hadassah on an ongoing basis, either through product licensing or by establishing start-up companies under the auspices of Hadassah or Hadasit Bio-Holdings Ltd. (TASE:HDST).
Our Achievements - A Wide Range of Medical Patents
Hadasit has gained global recognition for successfully enterprising biomedical technologies developed at Hadassah. We currently boast a rich portfolio of over 300 families of medical patents covering a wide variety of novel therapeutics, diagnostics and medical devices. Of the more than 30 companies established by Hadasit, nine are currently operating under the publicly-traded Hadasit Bio-Holdings. In addition, dozens of research and license option agreements are in place with global strategic partners.
Our Activities
Promoting Investments – Hadasit’s key activity, as facilitator and partner, is to seek
life science investors – private, institutional, and corporate – for innovative biomedical technologies originating at Hadassah.
Consulting - Tapping into the wealth of knowledge at Hadassah, we also provide consulting services to entrepreneurs, investors, and life science companies via our medical and scientific experts from the entire range of therapeutic and diagnostic specialties.
Contracting Clinical Trials - Over 200 clinical trials were conducted at Hadassah during 2007 by pharma, device, and biotech companies from across the globe. With a seasoned clinical staff and a proven track-record, this prestigious teaching hospital is a frequent choice for companies seeking the highest standards. Hadasit handles the contractual aspects of all clinical trials conducted at Hadassah.
Our Resources
The Hadassah Clinical Research Center (HCRC) is a GCP-compliant, 15-bed unit located in the Hadassah-Hebrew University BioPark, offering pharma, device, and biotech companies a complete package of services and facilities for conducting Phase I and II clinical trials. The HCRC is particularly focused on adherence to schedule by expediting patient enrollment, IRB approval, and the availability of essential clinical experts. This, combined with an experienced research team, a large and diverse patient pool, access to a cost-effective GMP facility, and rigorous IRB standards, makes the HCRC an ideal choice. In addition, pre-clinical, Phase III and Phase IV studies can be conducted at the various Hadassah facilities.
The Hadassah Cardiovascular Innovation Center (HCIC) is Hadasit’s recently established accelerator focusing on the commercialization of new innovations generated by Hadassah’s Heart Institute clinicians.
The Hadassah-Hebrew University BioPark, slated for launch in 2008, will be Israel’s first technology park for R&D-based medical technology companies, located on Hadassah’s Ein Kerem medical campus. Biotech, Pharma and medical device companies at the BioPark will benefit from close proximity to the rich infrastructure and extensive facilities of the Hebrew University schools of medicine, dentistry, pharmacy, nursing and public health, and the Hadassah University Hospital.
